JP2025525364A5 - - Google Patents
Info
- Publication number
- JP2025525364A5 JP2025525364A5 JP2024574683A JP2024574683A JP2025525364A5 JP 2025525364 A5 JP2025525364 A5 JP 2025525364A5 JP 2024574683 A JP2024574683 A JP 2024574683A JP 2024574683 A JP2024574683 A JP 2024574683A JP 2025525364 A5 JP2025525364 A5 JP 2025525364A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- pharmaceutically acceptable
- acceptable salt
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025216661A JP2026041858A (ja) | 2022-06-28 | 2025-12-02 | Ａｘｌの阻害剤としての化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263356421P | 2022-06-28 | 2022-06-28 | |
| US63/356,421 | 2022-06-28 | ||
| PCT/US2023/069124 WO2024006726A2 (en) | 2022-06-28 | 2023-06-27 | Compounds as inhibitors of axl |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025216661A Division JP2026041858A (ja) | 2022-06-28 | 2025-12-02 | Ａｘｌの阻害剤としての化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025525364A JP2025525364A (ja) | 2025-08-05 |
| JP2025525364A5 true JP2025525364A5 (https=) | 2025-10-02 |
| JP7785209B2 JP7785209B2 (ja) | 2025-12-12 |
Family
ID=89324379
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024574683A Active JP7785209B2 (ja) | 2022-06-28 | 2023-06-27 | Ａｘｌの阻害剤としての化合物 |
| JP2025216661A Pending JP2026041858A (ja) | 2022-06-28 | 2025-12-02 | Ａｘｌの阻害剤としての化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025216661A Pending JP2026041858A (ja) | 2022-06-28 | 2025-12-02 | Ａｘｌの阻害剤としての化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20230416277A1 (https=) |
| EP (1) | EP4547246A2 (https=) |
| JP (2) | JP7785209B2 (https=) |
| KR (1) | KR20250027650A (https=) |
| CN (1) | CN119365453A (https=) |
| AR (1) | AR129722A1 (https=) |
| AU (1) | AU2023298047A1 (https=) |
| CA (1) | CA3260468A1 (https=) |
| CL (1) | CL2024004060A1 (https=) |
| IL (1) | IL317736A (https=) |
| MX (1) | MX2024015648A (https=) |
| TW (1) | TW202400603A (https=) |
| WO (1) | WO2024006726A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR129722A1 (es) | 2022-06-28 | 2024-09-18 | Arcus Biosciences Inc | Compuestos inhibidores de axl |
| WO2024233360A1 (en) | 2023-05-05 | 2024-11-14 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| EP4720055A1 (en) | 2023-05-25 | 2026-04-08 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| US20260116868A1 (en) | 2023-10-06 | 2026-04-30 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| TW202523302A (zh) | 2023-11-02 | 2025-06-16 | 美商阿克思生物科學有限公司 | 噻唑化合物及其使用方法 |
| WO2025137370A1 (en) * | 2023-12-20 | 2025-06-26 | Arcus Biosciences, Inc. | Salt forms of an axl inhibitor |
| WO2025250276A1 (en) * | 2024-05-28 | 2025-12-04 | Taiho Pharmaceutical Co., Ltd. | Methods for treatment of non-small cell lung cancers |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7361764B2 (en) | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| EP1828180A4 (en) * | 2004-12-08 | 2010-09-15 | Glaxosmithkline Llc | 1H-pyrrolo [2,3-BETA] PYRIDINE |
| PT1906965E (pt) * | 2005-06-22 | 2015-09-03 | Chemocentryx Inc | Compostos de azaindazol e métodos de utilização |
| CA2710046C (en) | 2006-12-29 | 2016-02-09 | Rigel Pharmaceuticals, Inc. | N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors |
| EP2078010B1 (en) | 2006-12-29 | 2014-01-29 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| JP2010514810A (ja) | 2006-12-29 | 2010-05-06 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ａｘｌインヒビターとして有用な置換トリアゾール |
| ES2537480T3 (es) | 2008-07-09 | 2015-06-08 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos con heteroarilo policíclicos útiles como inhibidores de Axl |
| PL2387395T3 (pl) | 2009-01-16 | 2015-03-31 | Rigel Pharmaceuticals Inc | Inhibitory Axl do zastosowania w terapii skojarzonej do zapobiegania, leczenia lub postępowania z nowotworem przerzutowym |
| EP3444251B1 (en) * | 2013-12-11 | 2023-06-07 | Biogen MA Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
| GB201509338D0 (en) | 2015-05-29 | 2015-07-15 | Bergenbio As | Combination therapy |
| CN112243439A (zh) * | 2018-06-13 | 2021-01-19 | 百济神州有限公司 | 作为hpk1抑制剂的吡咯并[2,3-b]吡啶或吡咯并[2,3-b]吡嗪及其用途 |
| CA3108732A1 (en) * | 2018-08-28 | 2020-03-05 | Merck Patent Gmbh | Fused imidazopyridines as reversible inhibitors of bruton's tyrosine kinase (btk) |
| WO2020103896A1 (en) * | 2018-11-22 | 2020-05-28 | Beigene, Ltd. | Pyrrolo[2,3-b]pyridines as hpk1 inhibitor and uses thereof |
| TWI848141B (zh) | 2019-07-04 | 2024-07-11 | 英屬開曼群島商百濟神州有限公司 | 及其用途 |
| US12459958B2 (en) * | 2019-07-17 | 2025-11-04 | Beone Medicines I Gmbh | Tricyclic compounds as HPK1 inhibitor and the use thereof |
| ES3060629T3 (en) * | 2019-10-30 | 2026-03-27 | Biogen Ma Inc | Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase |
| WO2021239133A1 (zh) | 2020-05-29 | 2021-12-02 | 南京正大天晴制药有限公司 | 作为axl抑制剂的嘧啶类化合物 |
| WO2022184152A1 (zh) | 2021-03-03 | 2022-09-09 | 劲方医药科技(上海)有限公司 | 稠环取代的六元杂环化合物及其制法和用途 |
| EP4341261A1 (en) * | 2021-05-21 | 2024-03-27 | Arcus Biosciences, Inc. | Axl compounds |
| WO2022246179A1 (en) | 2021-05-21 | 2022-11-24 | Arcus Biosciences, Inc. | Axl inhibitor compounds |
| CN115504967A (zh) | 2021-06-23 | 2022-12-23 | 南京正大天晴制药有限公司 | 作为axl抑制剂的1,2,4-三唑化合物 |
| AR129722A1 (es) | 2022-06-28 | 2024-09-18 | Arcus Biosciences Inc | Compuestos inhibidores de axl |
-
2023
- 2023-06-26 AR ARP230101639A patent/AR129722A1/es unknown
- 2023-06-27 US US18/341,844 patent/US20230416277A1/en active Pending
- 2023-06-27 AU AU2023298047A patent/AU2023298047A1/en active Pending
- 2023-06-27 CN CN202380047386.9A patent/CN119365453A/zh active Pending
- 2023-06-27 CA CA3260468A patent/CA3260468A1/en active Pending
- 2023-06-27 WO PCT/US2023/069124 patent/WO2024006726A2/en not_active Ceased
- 2023-06-27 JP JP2024574683A patent/JP7785209B2/ja active Active
- 2023-06-27 EP EP23832486.7A patent/EP4547246A2/en active Pending
- 2023-06-27 TW TW112123754A patent/TW202400603A/zh unknown
- 2023-06-27 KR KR1020247041573A patent/KR20250027650A/ko active Pending
- 2023-06-27 IL IL317736A patent/IL317736A/en unknown
-
2024
- 2024-08-14 US US18/805,490 patent/US12195482B1/en active Active
- 2024-12-16 MX MX2024015648A patent/MX2024015648A/es unknown
- 2024-12-27 CL CL2024004060A patent/CL2024004060A1/es unknown
-
2025
- 2025-12-02 JP JP2025216661A patent/JP2026041858A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025525364A5 (https=) | ||
| JP2024521706A5 (https=) | ||
| CN101917982B (zh) | 使用4-碘-3-硝基苯甲酰胺与抗肿瘤剂组合治疗乳腺癌 | |
| CN105683201B (zh) | 新的含n‑杂环碳烯配体的金(iii)络合物、合成及其在癌症治疗和硫醇检测中的应用 | |
| US20150320784A1 (en) | Effective treatment of tumors and cancer with triciribine and related compounds | |
| JP2011522773A5 (https=) | ||
| JP2011500684A (ja) | ベンゾピロン系ｐａｒｐ阻害剤を用いる癌の処置方法および組成物 | |
| CN105452258B (zh) | 使用双核金(i)化合物用于癌症治疗的方法 | |
| TW201834696A (zh) | 藉由投予抗her3抗體－藥物複合體之egfr－tki抗性之非小細胞肺癌的治療方法 | |
| JP2003504413A (ja) | 抗腫瘍物質を含む組み合わせ調製物 | |
| JP2022527476A5 (https=) | ||
| JP2015531367A (ja) | ベリノスタットおよびトラベクテジンを用いる併用療法 | |
| TW201127384A (en) | Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent | |
| TW202537643A (zh) | 抗體-藥物結合物之用途 | |
| JP2022508935A (ja) | がん治療における免疫モジュレーションのための組合せ | |
| TW202400241A (zh) | 包含ｓｔｉｎｇ促效劑之抗體藥物共軛物、組合及使用方法 | |
| WO2021129616A1 (zh) | 抗pd-1抗体和组蛋白去乙酰化酶抑制剂的药物组合及其用途、使用方法 | |
| JP7183371B2 (ja) | 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット | |
| JP7132848B2 (ja) | 癌の治療のための合理的併用療法 | |
| JPWO2022270524A5 (https=) | ||
| JP7479292B2 (ja) | 組み合わせ医薬として用いられるｅｚｈ１／２二重阻害剤を含有する医薬組成物 | |
| RU2007145932A (ru) | Способ лечения устойчивого к лекарственным средствам рака | |
| US20210023211A1 (en) | Combination of anti-fgfr4-antibody and bile acid sequestrant | |
| TWI908128B (zh) | 靶向 Claudin 18.2 的抗體 - 藥物偶聯物用於治療實體瘤的方法 | |
| JP2024511354A5 (https=) |